Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-009 (amatuximab) plus pemetrexed and cisplatin in unresectable malignant pleural mesothelioma
2008-005448-18Phase 2Completed
- Sponsor
- Morphotek
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amatuximab in pleural mesothelioma, sponsored by Morphotek. Primary endpoint: Progression-free survival. Started Feb 2009; status: completed.
02
Drugs
amatuximab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2008-005448-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005448-18.